FindTrial
Sign In

3 PERIOD FASTING STUDY IN HEALTHY, ADULT, MALES, RANDOMLY DOSED IN EACH PERIOD WITH 2000mg OF CURCUMINOIDS FROM LIQUID CURCUMIN or with CURCUMINOID POWDER WITH TURMERIC ESSENTIAL OIL IN VEGETARIAN CAPSULES OR WITH CURCUMINOID POWDER WITH PIPERINE IN VEGETARIAN CAPSULES

An open-label, balanced, randomized, single-dose, three-treatment, three-period, three-sequence, three-way crossover, oral relative bioavailability study of 2000mg of Curcuminoids from Liquid Curcumin of Halcyon Bioscience Pty Ltd, Sydney, Australia with 2000mg of Curcuminoids from reference product 1 (R1) - Curcuminoid Powder with Turmeric essential oil in vegetarian capsules and 2000mg of Curcuminoids from reference product 2 (R2) - Curcuminoid powder with Piperine in vegetarian capsules in normal, healthy, adult, human male subjects under fasting condition. - NA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/04/018513
Enrollment
9
Registered
2019-04-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: 2000mg of curcuminoids from Liquid Curcumin: Halycon Bioscience Pty Ltd Single dose, three treatment, three period orally administered with 7 days washout and total duration of therapy

Sponsors

Halycon Bioscience pty Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Healthy adult human volunteers of age between 18-45 years

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Bio availabilityTimepoint: 14 time points, 00.00, 0.50, 01.00, 01.50, 02.00, 02.50, 03.00, 03.50, 04.00, 05.00, 06.00, 08.00, 10.00, 12.00—

Secondary

MeasureTime frame
To Monitor the adverse events and to ensure the safety and tolerability of the study subjectsTimepoint: 00.00, 0.50, 01.00, 01.50, 02.00, 02.50, 03.00, 03.50, 04.00, 05.00, 06.00, 08.00, 10.00, 12.00—

Countries

India

Contacts

Public ContactDr Reene Rajan

Micro Therapeutic Research Labs Pvt. Ltd

reenee@microtheraps.com9940502533

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026